PCA
KLDO

Peddock Capital Advisors’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Peddock Capital Advisors’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-275
Closed -$3K – 296
2020
Q4 		$3K Buy
+275
New +$2.26K ﹤0.01% 257

Other funds holding KLDO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Peddock Capital Advisors's KLDO Position: Q1 2021 in Review

Peddock Capital Advisors sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q1 2021, closing a stake of 275 shares — an estimated $3K sold.

Peddock Capital Advisors first reported a position in KLDO in Q4 2020 and held it in 1 quarter. The position peaked at $3K in Q4 2020. 71 funds tracked by Wall St. Rank hold KLDO as of Q1 2021.

  • Peddock Capital Advisors reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Peddock Capital Advisors sold 275 Kaleido Biosciences, Inc. Common Stock shares in Q1 2021, an estimated $3K.
  • Peddock Capital Advisors first reported a position in Kaleido Biosciences, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Peddock Capital Advisors's Kaleido Biosciences, Inc. Common Stock position peaked at $3K in Q4 2020.
  • 71 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q1 2021.

Based on Peddock Capital Advisors's 13F filing for Q1 2021, filed 17 May 2021.